IOP Reduction in Pigmentary Glaucoma Using DSLT
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
AgeNot listed
SponsorMann Eye Institute
About this trial
This study is a single-site, single-arm, prospective, observational study of IOP reduction after DSLT. Subjects will be assessed up to 12 months post-operatively. Clinical evaluations will include IOP and number of glaucoma medications.
Eligibility criteria
Qualifiers
Adult patients with pigmentary dispersion syndrome with elevated IOP or mild to moderate (based on AAO Preferred Practice Program criteria) pigmentary glaucoma with glaucomatous optic neuropathy and corresponding visual field/RNFL loss.
Treatment naive, or washed out IOP ranging from ≥18-34 mmHg
Central corneal thickness (CCT) 480-600 µm
Able to complete medication washout and follow-up
Disqualifiers
Prior incisional glaucoma surgery or glaucoma-related procedures in the study eye
Prior laser trabeculoplasty <3 years
Prior intraocular surgery and refractive surgery, except for cataract surgery unless greater than 2 years
Patients anticipating cataract surgery within the follow-up period
Trial design
Treatments tested in this trial
- Voyager DSLT
Treatment groups
No treatment groups listed
Sponsors and collaborators
Mann Eye Institute
Lead sponsor
Sengi
Collaborator
Source ClinicalTrials.gov